EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong

Yingcheng Wang, Mingjun Rui, Qiran Wei, Ting Fan Leung iD, Joyce H S You iD

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Yingcheng Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Cost-Benefit Analysis, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirsevimab, a long‐acting monoclonal antibody, was shown to prevent respiratory syncytial virus (RSV) infections in newborns. We evaluated the cost‐effectiveness of nirsevimab strategies for newborns from the societal perspective in Hong Kong.

Methods

A Markov model was developed to simulate outcomes of four nirsevimab strategies in newborns: (1) year‐round, (2) seasonal, (3) catch‐up, and (4) no nirsevimab. Primary outcomes included RSV lower respiratory tract infections (LRTI) related events, direct and indirect costs, quality‐adjusted life year (QALY) loss, and incremental cost per QALY (ICER).

Results

In base‐case analysis, all strategies with nirsevimab reduced RSV–LRTI‐related events. The catch‐up group had the lowest QALY loss per 100,000 infants (38.82), followed by year‐round (45.71), seasonal (60.60), and no intervention groups (81.52). Three nirsevimab cost levels were examined: 10%, 25%, and 50% of the US cost. At 10% US cost (USD52), all strategies were cost‐saving versus no intervention. At 25% US cost (USD130), the ICER of the catch‐up group (vs. no intervention) was 141,925 USD/QALY. At 50% US cost (USD260), all nirsevimab strategies were not cost‐effective versus no intervention at a willingness‐to‐pay of 162,401 USD/QALY. Influential factors with thresholds were identified for RSV‐LRTI incidence, RSV‐related hospitalization and mortality, and nirsevimab effectiveness at the 25% US cost level (USD130). In probabilistic sensitivity analysis, the catch‐up and no intervention strategies were cost‐effective 100% of the time at 10% (USD52) and 50% (USD260) US cost, respectively. At 25% US cost (USD130), the catch‐up strategy was cost‐effective 58.56% of the time.

Conclusions

The cost‐effectiveness acceptance of nirsevimab was highly subject to drug cost and effectiveness of nirsevimab, RSV‐LRTI incidence, and RSV–LRTI‐related consequences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsCost-Benefit AnalysisAntiviral AgentsAntibodies, Monoclonal, HumanizedHumansHong KongInfant, NewbornQuality-Adjusted Life YearsMarkov ChainsFemaleMaleInfantCost-Effectiveness Analysis

Stichwörter der Autor:innen

catch‐up schedulecost‐effectivenessnewbornsnirsevimabseasonal immunization scheduleyear‐round immunization schedule

Substanzen

Antiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Ting Fan Leung, Joyce H S You

Zitieren

APA

Wang, Y., Rui, M., Wei, Q., Leung, T. F., & You, J. H. S. (2025). Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70153

Vancouver

Wang Y, Rui M, Wei Q, Leung TF, You JHS. Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70153

BibTeX
@article{Wang2025,
  author = {Wang, Yingcheng and Rui, Mingjun and Wei, Qiran and Leung, Ting Fan and You, Joyce H S},
  title = {Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70153}
}
Kostenlos starten →